EGFR and adrenal cortex carcinoma: Lastly, lapatinib, a double inhibitor of EGFR and erbB2, approved to be used on treatment of breast cancer HER 2+ was used in ACC patients and revealed no objective response, but 52% (15/19) of assessable patients had SD and 60% (9/15) had SD ≥ 6 months.